OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans

Health Pharma & Biotech Written by: Emily Jarvie 08:33 Mon 20 Jul 2026 --> Proactive has a commercial relationship with OKYO Pharma Ltd. This article was produced independently under Proactive's Editorial Standards Policy . Disclaimer No investment advice About this content Editorial Standards & Policies Share article About this content × About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The Canberra Times, and... Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a forward looking and enthusiastic technology adopter. Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. OKYO Pharma Ltd ( NASDAQ:OKYO ) View Price & Profile OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans Published: 08:33 20 Jul 2026 EDT OKYO Pharma Ltd (NASDAQ:OKYO) announced on Monday that it has filed its annual report on Form 20-F for the fiscal year ended March 31, 2026, with the US Securities and Exchange Commission, while outlining its financial position and progress toward a planned Phase 3 clinical trial for its lead drug candidate. The clinical-stage biopharmaceutical company said the annual report is available through the SEC and its investor relations website. Alongside the filing, OKYO highlighted its recent financing activities, noting it raised approximately $25 million during the fiscal year, including a February 2026 public offering that generated about $22 million in gross proceeds, including the exercise of an overallotment option. "We are pleased to announce the filing of our annual report, which reflects substantial progress across our operations," Chief Financial Officer Keeren Shah wrote in the release. "During the year we raised approximately $25 million, including the recent capital raise backed by renowned investment funds, which has strengthened our cash position and provides us with ample financial resources to complete the NEPTUNE Phase 3 pivotal trial for urcosimod. This advances us toward potential registration, creating long-term value for patients and shareholders." The company reported cash and cash equivalents of approximately $20.6 million as of the end of March 2026, which it said is expected to fund operations through completion of the planned global Phase 3 pivotal trial for urcosimod, its investigational treatment for neuropathic corneal pain. OKYO plans to begin the Phase 3 NEPTUNE trial in the second half of 2026. The study is expected to enroll about 111 patients across the US and Europe, with participants randomized in a 2:1 ratio to receive either 0.05% urcosimod or placebo in a single-dose regimen The company said the trial design follows positive feedback from the US Food and Drug Administration during a Type D meeting and is intended to serve as a potential registrational study that could support a single-trial approval pathway. Continue reading